Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation

References

• Pham DD, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm 2015;478:517–529
   PubMed Web of Science ®Google Scholar
• Singh H, Jindal S, Singh M, et al. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. Int J Pharm 2015;485:138–151
   PubMed Web of Science ®Google Scholar
• Sukhithasri V, Vinod V, Varma S, Biswas R. Mycobacterium tuberculosis treatment modalities and recent insights. Curr Drug Deliv 2014;11:744–752
   PubMed Web of Science ®Google Scholar
• Chan JG, Tyne AS, Pang A, et al. Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. Int J Antimicrob Agents 2015;45:319–323
   PubMed Web of Science ®Google Scholar
• Das S, Tucker I, Stewart P. Inhaled dry powder formulations for treating tuberculosis. Curr Drug Deliv 2015;12:26–39
   PubMed Web of Science ®Google Scholar
• Kaur M, Garg T, Narang RK. A review of emerging trends in the treatment of tuberculosis. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print]. doi: 10.3109/21691401.2014.962745
   Web of Science ®Google Scholar
• Pourshahab PS, Gilani K, Moazeni E, et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J Microencapsul 2011;28:605–613
   PubMed Web of Science ®Google Scholar
• Chaubey P, Mishra B. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis. Carbohydr Polym 2014;101:1101–1108
   PubMed Web of Science ®Google Scholar
• Rastogi R, Sultana Y, Ali A, Aqil M. Particulate and vesicular drug carriers in the management of tuberculosis. Curr Drug Deliv 2006;3:121–128
   PubMedGoogle Scholar
• Kaur M, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst 2014;31:49–88
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents 2005;26:298–303
   PubMed Web of Science ®Google Scholar
• Lee KY, Mooney DJ. Alginate: properties and biomedical applications. Prog Polym Sci 2012;37:106–126
   PubMed Web of Science ®Google Scholar
• Sayag J, Meaume S, Bohbot S. Healing properties of calcium alginate dressings. J Wound Care 1996;5:357–362
   PubMedGoogle Scholar
• Ahmad Z, Sharma S, GK K. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 2007;3:239–243
   PubMed Web of Science ®Google Scholar
• Bhutani H, Singh S, Jindal KC. Drug-drug interaction studies on first-line anti-tuberculosis drugs. Pharm Dev Technol 2005;10:517–524
   PubMed Web of Science ®Google Scholar
• Agrawal S, Kaur KJ, Singh I, et al. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm 2002;233:169–177
   PubMed Web of Science ®Google Scholar
• Avachat AM, Bhise SB. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin. Pharm Dev Technol 2011;16:127–136
   PubMed Web of Science ®Google Scholar
• Koch K, Dew B, Corcoran TE, et al. Surface tension gradient driven spreading on aqueous mucin solutions: a possible route to enhanced pulmonary drug delivery. Mol Pharm 2011;8:387–394
   PubMed Web of Science ®Google Scholar
• Bohr A, Ruge CA, Beck-Broichsitter M. Preparation of nanoscale pulmonary drug delivery formulations by spray drying. Adv Exp Med Biol 2014;811:183–206
   PubMed Web of Science ®Google Scholar
• Beck-Broichsitter M, Schweiger C, Schmehl T, et al. Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. J Control Release 2012;158:329–335
   PubMed Web of Science ®Google Scholar
• Yang WW, Pierstorff E. Reservoir-based polymer drug delivery systems. J Lab Autom 2012;17:50–58
   PubMedGoogle Scholar
• Kaur R, Garg T, Malik B, et al. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv 2014. [Epub ahead of print]. doi: 10.3109/10717544.2014.920428
   PubMed Web of Science ®Google Scholar
• Yousefi S, Emam-Djomeh Z, Mousavi SM. Effect of carrier type and spray drying on the physicochemical properties of powdered and reconstituted pomegranate juice (Punica Granatum L.). J Food Sci Technol 2011;48:677–684
   PubMed Web of Science ®Google Scholar
• Son YJ, Worth Longest P, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm 2013;443:137–145
   PubMed Web of Science ®Google Scholar
• Badawy SI, Shah KR, Surapaneni MS, et al. Effect of spray-dried mannitol on the performance of microcrystalline cellulose-based wet granulated tablet formulation. Pharm Dev Technol 2010;15:339–345
   PubMed Web of Science ®Google Scholar
• Sou T, Orlando L, McIntosh MP, et al. Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: a design of experiment approach. Int J Pharm 2011;421:220–229
   PubMed Web of Science ®Google Scholar
• Nekkanti V, Muniyappan T, Karatgi P, et al. Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments. Drug Dev Ind Pharm 2009;35:1219–1229
   PubMed Web of Science ®Google Scholar
• Kaur R, Garg T, Das Gupta U, et al. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol 2014. [Epub ahead of print]. doi: 10.3109/21691401.2014.930747
   Web of Science ®Google Scholar
• Saraogi GK, Gupta P, Gupta UD, et al. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharm 2010;385:143–149
   PubMed Web of Science ®Google Scholar
• Krasucka DM, Kos K, Cybulski WA, et al. Karl Fisher determination of residual moisture in veterinary vaccines – practical implementation in market monitoring. Acta Pol Pharm 2012;69:1364–1367
   PubMed Web of Science ®Google Scholar
• Learoyd TP, Burrows JL, French E, Seville PC. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur J Pharm Biopharm 2008;68:224–234
   PubMed Web of Science ®Google Scholar
• Ezzati Nazhad Dolatabadi J, Hamishehkar H, Valizadeh H. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance. Drug Dev Ind Pharm 2015;41:1431–1437
   PubMed Web of Science ®Google Scholar
• Ortiz M, Jornada DS, Pohlmann AR, Guterres SS. Development of novel chitosan microcapsules for pulmonary delivery of dapsone: characterization, aerosol performance, and in vivo toxicity evaluation. AAPS PharmSciTech 2015. [Epub ahead of print]. doi: 10.1208/s12249-015-0283-3
   PubMed Web of Science ®Google Scholar
• Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech 2008;9:755–761
   PubMed Web of Science ®Google Scholar
• Tiruveedhula VV, Witzigmann CM, Verma R, et al. Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis. Bioorg Med Chem 2013;21:7830–7840
   PubMed Web of Science ®Google Scholar
• Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011;19:468–474
   PubMed Web of Science ®Google Scholar
• Alexander BD, Winkler TP, Shi S, et al. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm Dev Technol 2011;16:577–582
   PubMed Web of Science ®Google Scholar
• Bhatt NB, Barau C, Amin A, et al. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine-or efavirenz-based antiretroviral treatment. Antimicrob Agents Chemother 2014;58:3182–3190
   PubMed Web of Science ®Google Scholar
• Tian G, Longest PW, Li X, Hindle M. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv 2013;26:248–265
   PubMed Web of Science ®Google Scholar
• Saini D, Biris AS, Srirama PK, Mazumder MK. Particle size and charge distribution analysis of pharmaceutical aerosols generated by inhalers. Pharm Dev Technol 2007;12:35–41
   PubMed Web of Science ®Google Scholar
• Vehring R. Pharmaceutical particle engineering via spray drying. Pharm Res 2008;25:999–1022
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Charan C, Stults CL, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 2008;97:287–302
   PubMed Web of Science ®Google Scholar
• Nahar K, Gupta N, Gauvin R, et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 2013;49:805–818
   PubMed Web of Science ®Google Scholar